Iterum Therapeutics 提供 FDA 对 uUTI 治疗的磺罗培南治疗审查，预计将于 2024 年 10 月 25 日做出决定。 Iterum Therapeutics presents sulopenem for uUTI treatment review by FDA, with decision expected by October 25, 2024.
Iterum Therapeutics 将于 2024 年 9 月 9 日至 11 日在 H.C. Wainwright 全球投资会议上展示其首款化合物磺罗培南。 Iterum Therapeutics will present its first compound, sulopenem, at the H.C. Wainwright Global Investment Conference from September 9-11, 2024. 美国食品和药物管理局正在审查苏洛作为无并发性尿路感染 (UTI) 的治疗方法,但对其潜在的滥用及其对抗抗菌素耐药菌株的有效性提出了担忧. The FDA is reviewing sulopenem as a treatment for uncomplicated urinary tract infections (uUTIs) but has raised concerns about potential misuse and its efficacy against antimicrobial-resistant strains. 预计FDA将在2024年10月25日之前对批准作出决定. The FDA's decision on approval is expected by October 25, 2024. 如果获得批准,它将是首个用于治疗尿路感染的口服便秘抗生素. If approved, it would be the first oral penem antibiotic for uUTIs.